HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx-to-OTC Switch

Set Alert for Rx-To-OTC Switch

New UK Health Secretary Wants More OTCs Available And Greater Role For Pharmacists

More medicines available without a prescription and more responsibility for community pharmacists are two of the goals set out by the UK's new Secretary of State for Health and Social Care.

Europe United Kingdom

Akorn's Delay Moving Three Generics To OTC Leads To $7.9M Settlement In Medicare Billing Complaint

Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage. 

Prescription To OTC Switch Legal Issues

US FDA Checking Boxes On OTC Monograph Overhaul And In-Box For ACNU Switch Comments

“Who would have said that, looking forward two or three years ago, we would be where we are now?” says FDA OTC office director Theresa Michele. Monograph reform and introducing “additional conditions for nonprescription use” options for NDA OTCs each is a “real gamechanger.”

Prescription To OTC Switch OTC Drugs

MHRA Plan To Raise Fees Will See Big Hike For Switch Applications

UK regulator MHRA has set out a proposal to raise fees across the board by at least 10% for its regulatory work related to medicines and medical devices. A select number of fees will see even bigger increases, with the cost almost tripling for Rx-to-OTC switch applications.

OTC Drugs United Kingdom

Haleon’s EMEA Head Filippo Lanzi: There’s More To Innovation Than Rx-To-OTC Switch

Health literacy and natural alternatives are two areas where Haleon's EMEA and LATAM head Filippo Lanzi sees potential for growth, in addition to Rx-to-OTC switch, he tells HBW Insight in an exclusive interview. Lanzi also digs deeper into Haleon's recently published first-half sales and earnings results and shares his thoughts on how the firm will meet the multiple challenges posed by the current social and economic environment. 

Europe Health

Novo Nordisk Launches OTC HRT Treatment In UK

The first hormone replacement therapy drug sold without a prescription in the UK is now available in Boots pharmacies across the country.

Launches Prescription To OTC Switch

Over The Counter 5 Sept 2022: Self-Care Regulation After COVID, With Haleon/GSCF’s Ian Urquhart

In this episode, HBW Insight talks to Haleon’s global head of regulatory intelligence and policy, Ian Urquhart, about the innovative and flexible approaches that regulators took to ensuring access to medicines during the coronavirus pandemic. Urquhart speaks about his work with the Global Self-Care Federation, where the regulatory affairs committee which he chairs has been looking into what happened during the pandemic and drawing lessons for the future. Strengthening supply chains, Rx-to-OTC switch and e-commerce are all on the agenda for the organization, which has published a series of papers in these areas to inform future self-care policy and regulation across the world.

OTC Drugs Regulation

US FDA’s Proposed ACNU OTC ‘Failure’ Reports Requirement: Asking Too Much, Or Too Little?

Periodic summaries FDA is considering are “most effective method to track and report relevant concerns,” but “failure” as outlined in proposed rule is too broad, says CHPA. Digital care delivery firm Amwell says FDA should ask ACNU OTC marketers for some individual adverse event reports in addition to summaries.

See All